Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
about
Safe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingOfatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaNew developments in the management of chronic lymphocytic leukemia: role of ofatumumabThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trialThe regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Chronic lymphocytic leukemia (CLL)-Then and now.Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Recent advances in therapy of chronic lymphocytic leukaemia.Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.The safety profile of monoclonal antibodies for chronic lymphocytic leukemia.Current Treatment of Chronic Lymphocytic Leukemia.Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.Recent therapeutic advances in chronic lymphocytic leukemia.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients.Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
P2860
Q23923997-8A919DD0-E76D-40EB-8C5D-38C5DEF4E05FQ26738934-C53CEB20-0B5B-4446-A537-641C5758FD8AQ26765624-DCF45EC2-4B41-41BD-9863-562B43619EA6Q26768396-C904EDBE-FD52-4AD8-85FF-58AAA0781062Q26775506-F5719B7C-7E47-4892-97B6-C6CA939C82C9Q26783600-92B931D8-5399-45FA-8240-C04F0B204629Q30243968-5BBBBC4F-3AC1-4B29-9DA8-E1F297379D4CQ30252869-18AB92C2-F7BD-4E7E-A2AD-236C63C2C8B7Q36437030-FF587548-0DCC-45E0-9774-6AFE26E2CFEBQ36548443-6324F10A-45CE-48F5-933B-78CB0A47DF33Q37429218-D31B3F1C-424E-4B66-9259-E2A6BED2BDF8Q37633475-ECEF8D6D-F6BF-44DB-8347-8EA26D9B5018Q37747342-C4958A51-4714-443B-87C7-49DCBA8B3639Q38632940-19CC89B9-D5ED-451D-A650-AC63F3CACBFDQ38646074-FBB6A615-51A4-40A7-BA0B-E008964E7C86Q38675358-83746F3E-681E-4B94-B53D-B54C0E49F55DQ38691282-C751BE5A-38A7-4E44-9C6C-11144242730FQ38729031-DA52A36C-26F9-40DB-AFBD-5172467D1D57Q38818283-3F8B5443-61CB-4281-A05A-D5B86E7219DAQ38824182-8D994266-05C6-4D88-8DF2-8257CA248F23Q38851368-60FB6C2A-BD7F-4E84-AD6E-039C3ADE7B25Q38862525-E2A97A36-175A-4A4F-A4A1-4D84C9963B0BQ38881164-7739B4DA-1054-4017-8738-993D96835267Q38943877-27DE8BE5-848E-4384-8073-AC282AEA6170Q38978727-61EB00B5-A49B-463B-8CD2-4F3F4B8BF72FQ39018189-C53110DA-A239-4EE5-8F20-708474778BE5Q39129372-3B3A67FD-A79C-4A1D-AA4B-E8CC12A4132EQ39414732-1ED38ED8-5311-450E-B175-B428BAFE70A5Q41848521-77EC8B4E-1735-4FFD-85B7-22836958C19DQ42368314-6A8AEC27-D71C-4C77-8D08-0F4D429129C4Q46318389-BB0A524E-A1EF-4B96-A08B-AFEA97B9120BQ47424531-401BB46F-A56D-458F-80F7-3F5AFF0A8AABQ47780043-0773DFDC-5E8B-4928-9253-1F0C3EDE2F58Q47796704-8486C3D5-1CC9-485F-9E79-7D82EBB54938Q47898168-0B64BF6F-8143-445E-9AFB-D7E3F3E59652Q48125213-828043B5-0257-443C-BED9-93C3B3CA0A15Q50074012-4ADED5CF-89DC-4EE8-B716-9D674F4C83D7Q50121608-6E31F846-EC8B-4A6E-BECF-CBA6CB813268Q51386372-EF2B64E5-210B-4B68-AE9F-765432D152A8Q52645038-6810F036-1CB8-41D6-9E99-7D160143786E
P2860
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@ast
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@en
type
label
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@ast
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@en
prefLabel
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@ast
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@en
P2093
P2860
P1433
P1476
Safety and activity of BTK inh ...... leukemia: a phase 1b/2 study.
@en
P2093
Amy J Johnson
Amy S Ruppert
Brian Munneke
Danelle F James
Gerard Lozanski
Jamie-Sue West
Jeffrey A Jones
Jennifer A Woyach
Joseph M Flynn
Jutta K Neuenburg
P2860
P304
P356
10.1182/BLOOD-2014-12-617522
P407
P577
2015-06-26T00:00:00Z